Aimmune Therapeutics, Inc. 5,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 26th, 2018 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
Aimmune Therapeutics, Inc., a company incorporated under the laws of Delaware (the “Company”), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 825,000 additional shares of Common Stock. The aforesaid 5,500,000 shares of Common S
